GeNeuro SA
EPA:GNRO.PA
0.07 (EUR) • At close September 16, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | GeNeuro SA |
Symbool | GNRO.PA |
Munteenheid | EUR |
Prijs | 0.065 |
Beurswaarde | 1,922,523 |
Dividendpercentage | 0% |
52-weken bereik | 0.056 - 2.35 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Jesus Martin-Garcia |
Website | https://www.geneuro.com |
An error occurred while fetching data.
Over GeNeuro SA
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (EUR)
Cijfers zijn in miljoenen (EUR)